You are here: Industry Insights > BNT162B2

News List

Pfizer and BioNTech Provide Update on Omicron Variant AmericanPharmaceuticalReview
December 09, 2021
Pfizer Inc. and BioNTech SE announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from v
Press Release Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses FirstWordPharma
December 06, 2021
Preliminary Phase 2 study and a sub-study demonstrate value of mix-and-match approach; Johnson & Johnson booster increased neutralizing and binding antibodies, similar to boosting with BNT162b2, and showed strong increase in T-cell responses.
Odds of SARS-CoV-2 Infection Down After Third BNT162b2 Dose Drugs
December 06, 2021
Receipt of a third booster BNT162b2 dose is associated with a reduction in the odds of testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online Nov. 30 in JAMA Internal Medicine.
Prior SARS-CoV-2 Infection Ups Protection for Vaccinated Drugs
November 16, 2021
For individuals vaccinated with mRNA COVID-19 vaccines, prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a lower risk for breakthrough infection...
BioNTech’s 2Q Revenue Soars contractpharma
August 10, 2021
Growth due to rapid increases in the supply of BNT162b2 as BioNTech and Pfizer evaluate a third dose to boost efficacy against Delta variant.
Pfizer's 2Q Revenues Up 92% contractpharma
July 30, 2021
COVID-19 vaccine BNT162b2 contributes $7.8 billion in sales and alliance revenues.
Terry Gou to bid for Pfizer-BioNTech shots purchase before June 1 firstwordpharma
June 01, 2021
Taiwan, Chinaese billionaire businessman Terry Gou announced Sunday that he is putting together a bid to purchase the Pfizer-BioNTech COVID-19 vaccines for Taiwan, China that will be submitted within 72 hours, reported The China Post.
Pfizer 1Q Revenues up 45% Driven by COVID Vax contractpharma
May 06, 2021
Vaccine sales were $4.9 billion in the quarter, with BNT162b2 contributing $3.5 billion in global revenues.
Pfizer and BioNTech’s Covid-19 vaccine shows 100% efficacy in adolescents pharmaceutical-technology
April 02, 2021
Pfizer and BioNTech have reported that a Phase III trial of their Covid-19 vaccine, BNT162b2, showed 100% efficacy and strong antibody responses in adolescents aged 12 to 15 years with or without prior evidence of SARS-CoV-2 infection.
Positive results for Pfizer/BioNTech’s COVID-19 vaccine in 12-15 year olds pharmatimes
April 01, 2021
Pfizer and BioNTech have revealed positive top-line data for their COVID-19 vaccine – BNT162b2 – in adolescents aged 12 to 15 years old.

Previous page 1 2 3 Next page